Global Iron Chelation Drug Market Growth 2023-2029

Global Iron Chelation Drug Market Growth 2023-2029

In a healthy body, when the stores of iron are sufficient, the intestines reduce the absorption of this mineral from food and drink to prevent its levels from rising too high.

People with iron overload disorders absorb more iron than usual from food or supplements. The body cannot excrete the extra iron fast enough, so it continues to build up. The body stores it in organ tissue, mainly in the liver, as well as the heart and the pancreas.

There are several types of iron overload disorder. Hereditary hemochromatosis is a primary condition that has a genetic component. People can also have secondary hemochromatosis, which develops as a result of another disease or condition.

The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.

LPI (LP Information)' newest research report, the “Iron Chelation Drug Industry Forecast” looks at past sales and reviews total world Iron Chelation Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Iron Chelation Drug sales for 2023 through 2029. With Iron Chelation Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Iron Chelation Drug industry.

This Insight Report provides a comprehensive analysis of the global Iron Chelation Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Iron Chelation Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Iron Chelation Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Iron Chelation Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Iron Chelation Drug.

The global Iron Chelation Drug market size is projected to grow from US$ 699.4 million in 2022 to US$ 415.9 million in 2029; it is expected to grow at a CAGR of 415.9 from 2023 to 2029.

Global Iron Chelation Drug key players include Novartis, Chiesi Group, Sun Pharma, Cipla, Natco Pharma, etc. Global top five manufacturers hold a Revenue Market Share over 35%. Europe accounts for the most Sales Market Share, which have a share over 40%, followed by North America. In terms of product, Deferasirox is the largest segment, with a Revenue Market Share over 90%. And in terms of application, the largest Application is Transfusional Iron Overload, followed by NTDT Caused Iron Overload.

This report presents a comprehensive overview, market shares, and growth opportunities of Iron Chelation Drug market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Deferasirox
Deferoxamine
Deferiprone

Segmentation by application
Transfusional Iron Overload
NTDT Caused Iron Overload

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Chiesi Group
Sun Pharma
Cipla
Natco Pharma
Taro Pharm
Gland Pharma

Key Questions Addressed in this Report

What is the 10-year outlook for the global Iron Chelation Drug market?

What factors are driving Iron Chelation Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Iron Chelation Drug market opportunities vary by end market size?

How does Iron Chelation Drug break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.